Citation Information :
Aggarwal DG, Bhojraj SS, Behrainwalla A, Jani CK, Mehta SS. Phlegmasia cerulea dolens following heparin-induced thrombocytopenia. Indian J Crit Care Med 2018; 22 (1):51-52.
The authors present a case of a 49-year-old woman who underwent coronary artery bypass grafting after suffering from an acute coronary syndrome and later developed phlegmasia cerulea dolens with heparin-induced thrombocytopenia (HIT) and HIT thrombosis (HITT).
Kasper, DL. Harrisons Principles of Internal Medicine. 19th ed. New York: McGraw Hill Education Medical; 2015. p. 727-8.
Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252-61.
Veltchev LM, Kalniev MA, Todorov TA. Phlegmasia cerulea dolence-risk factors and prevention. Case report. J IMAB Annu Proc 2009;Book 1:89-91.
Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311S-337S.
Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 2006;107:2346-53.
Lo GK, Warkentin TE. Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: The “4 T's”. Blood 2003;102:536a.
Ortel TL. Heparin-induced thrombocytopenia: When a low platelet count is a mandate for anticoagulation. Hematology (Am Soc Hematol Educ Program) 2009;1:225-32.
